drugset / Trial / NCT00073216

Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

NCT00073216 ↗

RandomizedFactorialPrevention

Summary

To prevent HIV infection, a vaccine that produces strong HIV-specific humoral (B-cell) and cellular (T-cell) immune system responses is desirable. The purpose of this study is to test the safety of and immune response to a novel combination HIV vaccine in HIV uninfected adults. This study will also test the safety of and immune response to a protein vaccine given alone.

Timeline

Start
—
Primary completion
—
Completion
2007-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant Vaccine — —
Subject Clade B gag DNA/PLG and env DNA/PLG Microparticles Vaccine 250 ug Intramuscular
Subject Clade B gag DNA/PLG and env DNA/PLG Microparticles Vaccine 500 ug Intramuscular
Subject Clade B gag DNA/PLG and env DNA/PLG Microparticles Vaccine 1000 ug Intramuscular